Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity
Authors:
Open Access
- 22 March 2015
- journal article
- phase i-studies
- Published by Springer Nature in Investigational New Drugs
- Vol. 33 (3) , 611-620
Abstract
Summary: Background This trial evaluated the maximum tolerated dose (MTD), safety, pharmacokinetics, and activity of volasertib, a selective Polo-like kinase 1 inhibitor that induces mitotic arrest and apoptosis, combined with cisplatin or carboplatin in patients with advanced/metastatic solid tumors (NCT00969761; 1230.6). Methods Sequential patient cohorts (3 + 3 dose-escalation design) received a single infusion of volasertib (100–350 mg) with cisplatin (60–100 mg/m2) or carboplatin (area under the concentration versus time curve [AUC]4–AUC6) on day 1 every 3 weeks for up to six cycles. Sixty-one patients received volasertib/cisplatin (n = 30) or volasertib/carboplatin (n = 31) for a median of 3.5 (range, 1–6) and 2.0 (range, 1–6) treatment cycles, respectively. Results The most common cycle 1 dose-limiting toxicities (DLTs) were thrombocytopenia, neutropenia and fatigue. MTDs (based on cycle 1 DLTs) were determined to be volasertib 300 mg plus cisplatin 100 mg/m2 and volasertib 300 mg plus carboplatin AUC6. Co-administration did not affect the pharmacokinetics of each drug. Partial responses were observed in two patients in each arm. Stable disease was achieved in 11 and six patients treated with volasertib/cisplatin and volasertib/carboplatin, respectively. Conclusions Volasertib plus cisplatin or carboplatin at full single-agent doses was generally manageable and demonstrated activity in heavily pretreated patients with advanced solid tumors.Keywords
This publication has 22 references indexed in Scilit:
- Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant gliomaActa Histochemica, 2012
- Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cellsMedical Science Monitor, 2012
- Efficient Inhibition of Human Colorectal Carcinoma Growth by RNA Interference Targeting Polo-Like Kinase 1 In Vitro and In VivoCancer Biotherapy and Radiopharmaceuticals, 2011
- Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in OncologyThe Oncologist, 2009
- BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor ActivityClinical Cancer Research, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- PD2-1-1: Efficacy of BI 2536, a potent and selective inhibitor of the mitotic kinase Plk1, in models of human non-small cell lung carcinomaJournal of Thoracic Oncology, 2007
- Targeting polo-like kinase 1 for cancer therapyNature Reviews Cancer, 2006
- Clinical Pharmacokinetics and Dose Optimisation of CarboplatinClinical Pharmacokinetics, 1997
- Clinical Pharmacokinetics of CarboplatinClinical Pharmacokinetics, 1991